ArticleDermatology and therapy2026
Real-World Characteristics, Treatment Patterns, and Outcomes in Adult Patients Receiving Abrocitinib for Atopic Dermatitis in China: Interim Analysis from the AHEAD Registry.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Atopic Dermatitis Beyond the Skin Barrier: Precision Medicine Approaches to Immunological Profiling and Therapeutic Innovation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAtopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition that significantly impairs quality of life (QoL) and imposes a substantial socioeconomic burden. Abrocitinib, a selective Janus kinase 1 inhibitor, has shown promise in clinical trials, yet real-word data in Chinese patients remain limited. This interim analysis of the AHEAD (Abrocitinib Chinese rEgistry on Atopic Dermatitis, ChiCTR2400086045) registry aims to characterize treatment patterns and early effectiveness in real-world settings.
methodsAHEAD is an ongoing, prospective, multicenter, observational study enrolling adults with AD initiating abrocitinib across 42 sites in China. This interim analysis included data from 314 patients enrolled between 18 October 2023 and 30 April 2024, with assessments through week 12. Clinical effectiveness, QoL, adherence, and flare incidence were evaluated using validated physician- and patient-reported outcome measures.
resultsA total of 314 patients were enrolled. At baseline, most patients exhibited moderate to severe AD [mean Investigator's Global Assessment (IGA) score of 3.0; Eczema Area and Severity Index (EASI) score of 13.5] with impaired QoL [Dermatology Life Quality Index (DLQI) score of 12.0]. Treatment with abrocitinib led to rapid and sustained improvement across all measures through week 12: IGA (40% reduction), EASI (79%), Peak Pruritus Numerical Rating Scale (PP-NRS) (52%), Scoring AD (SCORAD) (62%), DLQI (48%), and Atopic Dermatitis Control Tool (ADCT) (55%). At week 12, 36.1% achieved IGA success (score of 0 or 1 with ≥ 2-grade improvement) and 61.6% reached EASI-75 (≥ 75% improvement in EASI). Improvements were observed as early as week 2. Adherence was high (96.8% with proportion of days covered ≥ 0.8), and flares were infrequent (7%).
conclusionPatients enrolled in AHEAD exhibited significant disease burden in AD signs and QoL. Abrocitinib provides early and sustained improvement in disease severity and QoL among Chinese adults with moderate to severe AD, with high adherence and low flare rates.
trial registrationChiCTR2400086045.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.